Italia markets closed

Dow Jones
34.364,50
+99,13(+0,29%)
Nasdaq
13.855,13
+86,21(+0,63%)
Nikkei 225
27.588,37
+66,11(+0,24%)
EUR/USD
1,1324
-0,0031(-0,27%)
BTC-EUR
32.786,69
+1.400,49(+4,46%)
CMC Crypto 200
844,40
+33,80(+4,17%)

Grifols, S.A. (GRF.MC)

MCE - MCE Prezzo differito. Valuta in EUR.

Aggiungi a portafoglio

15,36

-1,25

(-7,52%)

Alla chiusura: 05:35PM CET

Capitalizzazione	9,161B
Beta (5 anni mensile)	0,19
Rapporto PE (ttm)	15,86
EPS (ttm)	0,97
Prossima data utili	24 feb 2022 - 28 feb 2022
Rendimento e dividendo (forward)	0,36 (2,19%)
Data ex dividendo	03 giu 2021
Stima target 1A	25,40

Tutte

GlobeNewswire
GigaGen Doses First Patient in Phase 1 Trial of Recombinant Hyperimmune Polyclonal Antibody GIGA-2050 for COVID-19
First-in-human study evaluating recombinant hyperimmunes SOUTH SAN FRANCISCO, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today the first patient has been dosed in its Phase 1 clinical trial of GIGA-2050, the company’s recombinant hyperimmune polyclonal antibody drug designed to provide passive immunity